Author

D. Bulanova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Approach:genetic perturbation / CRISPR· 2 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

K. Wennerberg· 3 shared J. Hynninen· 2 shared J. Oikkonen· 2 shared L. Gall-Mas· 2 shared S. Hautaniemi· 2 shared W. Senkowski· 2 shared Y. Akimov· 2 shared A. Bugai· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. Wennerberg

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low dose treatment of high-grade serous ovarian carcinoma

J. Benada, D. Bulanova, V. Azzoni, V. Petrosius, S. Ghazanfar, K. Wennerberg, C. S. Sorensen

This study shows that combining low-dose WEE1 and PKMYT1 inhibition synergistically kills ovarian cancer cells by increasing genomic instability and inflammation, and is well-tolerated in mice.

bioRxiv · Mar 31, 2023Cancer Biology

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

D. Bulanova, Y. Akimov, W. Senkowski, J. Oikkonen, L. Gall-Mas, S. Timonen, M. Elmadani, J. Hynninen, S. Hautaniemi, T. Aittokallio, K. Wennerberg

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

bioRxiv · Nov 14, 2022 · PreprintCancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology

Chemical, physical and biological triggers of Bcl-xL-mediated apoptosis

A. Ianevski, E. Kulesskiy, K. Krpina, G. Lou, Y. Aman, A. Bugai, K. Aasumets, Y. Akimov, D. Bulanova, K. Gildemann, A. F. Arutyunyan, O. Y. Susova, A. L. Zhuze, P. Ji, W. Wang, , D. E. Kainov

This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.

bioRxiv · Jan 13, 2020Cancer Biology